Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tislelizumab + re-TURBT in High-Risk NMIBC
NCT06630871Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, tislelizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Fujian Medical University Union Hospital. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
disitamab vedotintislelizumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06630871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630871.